Background

• In 2018, the Multiple Sclerosis (MS) world received its first true generic DMT, and more generics will become available over the next few years.
• Studies in other disease states have shown a nocebo effect due to a mistrust of generic medications, leading
  to worse clinical outcomes and higher medical costs when patients are mandated to switch from a branded maintenance medication to a generic.
• To learn if there could be a risk of a nocebo effect for patients with MS, this study focused on understanding patients’ views towards generic DMTs.

Objectives

Primary: Measuring the views of patients with MS toward generic DMTs.

Secondary: Observe opportunities for pharmacists to impact patient DMT trust through counseling.

Read the Outcomes Study by submitting the form below.

​